Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.
Experts from various institutions were interviewed by OncLive® at the 24th Annual International Lung Cancer Congress® about the ongoing platinum chemotherapy shortage in the United States.
Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.